Table 1:

CNS penetrating efficiency (CPE) of anti-retroviral drugs used in HIV treatment.

CNS penetrating efficiency (CPE)
Drug Class	4	3	2	1	Non-classified
Nucleoside Reverse Transcriptase Inhibitors	Zidovudine	Abacavir	Didanosine	Tenofovir
		Emtricitabine	Stavudine	Zalcitabine
		Emtricitabine	Lamivudine	Zalcitabine
Nonnucleoside Reverse Transcriptase Inhibitors	Nevirapine	Delavirdine	Etravirine		Rilpivirine: CSF/Plasma ratio 1.2–1.6% but above IC₅₀
Nonnucleoside Reverse Transcriptase Inhibitors	Nevirapine	Efavirenz	Etravirine		Rilpivirine: CSF/Plasma ratio 1.2–1.6% but above IC₅₀
Protease	Indinavir/r	Darunavir/r	Atazanavir	Nelfinavir
Inhibitors		Fosamprenavir/r	Atazanavir/r	Ritonavir
		Indinavir	Fosamprenavir/r	Saquinavir
		Lopinavir/r		Saquinavir/r
		Lopinavir/r		Tipranavir/r
Entry/Fusion	Vicriviroc	Maraviroc		Enfuvirtide
Inhibitors	Vicriviroc	Maraviroc		Enfuvirtide
Integrase		Raltegravir			Dolutrgravir: CSF/Plasma ratio 0.467–0.546% but above IC₅₀
Inhibitors					Dolutrgravir: CSF/Plasma ratio 0.467–0.546% but above IC₅₀
					Elvitegravir:
					No data (clinical study underway UCSD, Letendre S.)